|
1
|
Ozols RF: Systemic therapy for ovarian
cancer: Current status and new treatments. Semin Oncol. 33 2 Suppl
6:S3–S11. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liao J, Qian F, Tchabo N,
Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB,
Morrison CD, et al: Ovarian cancer spheroid cells with stem
cell-like properties contribute to tumor generation, metastasis and
chemotherapy resistance through hypoxia-resistant metabolism. PLoS
One. 9:e849412014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Foster R, Buckanovich RJ and Rueda BR:
Ovarian cancer stem cells: Working towards the root of stemness.
Cancer Lett. 338:147–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shield K, Ackland ML, Ahmed N and Rice GE:
Multicellular spheroids in ovarian cancer metastases: Biology and
pathology. Gynecol Oncol. 113:143–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burleson KM, Boente MP, Pambuccian SE and
Skubitz AP: Disaggregation and invasion of ovarian carcinoma
ascites spheroids. J Transl Med. 4:62006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shen-Gunther J and Mannel RS: Ascites as a
predictor of ovarian malignancy. Gynecol Oncol. 87:77–83. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ayantunde AA and Parsons SL: Predictors of
poor prognosis in patients with malignant ascites: A prospective
study. Clin Med Diagnostics. 2:1–6. 2012. View Article : Google Scholar
|
|
8
|
Mackey JR and Venner PM: Malignant
ascites: Demographics, therapeutic efficacy and predictors of
survival. Can J Oncol. 6:474–480. 1996.PubMed/NCBI
|
|
9
|
Mills GB, May C, Hill M, Campbell S, Shaw
P and Marks A: Ascitic fluid from human ovarian cancer patients
contains growth factors necessary for intraperitoneal growth of
human ovarian adenocarcinoma cells. J Clin Invest. 86:851–855.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mutsaers SE: Mesothelial cells: Their
structure, function and role in serosal repair. Respirology.
7:171–191. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Burleson KM, Casey RC, Skubitz KM,
Pambuccian SE, Oegema TR Jr and Skubitz AP: Ovarian carcinoma
ascites spheroids adhere to extracellular matrix components and
mesothelial cell monolayers. Gynecol Oncol. 93:170–181. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Strobel T and Cannistra SA:
Beta1-integrins partly mediate binding of ovarian cancer cells to
peritoneal mesothelium in vitro. Gynecol Oncol. 73:362–367. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mikuła-Pietrasik J, Sosińska P and Książek
K: Resveratrol inhibits ovarian cancer cell adhesion to peritoneal
mesothelium in vitro by modulating the production of α5β1 integrins
and hyaluronic acid. Gynecol Oncol. 134:624–630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cannistra SA, Kansas GS, Niloff J,
DeFranzo B, Kim Y and Ottensmeier C: Binding of ovarian cancer
cells to peritoneal mesothelium in vitro is partly mediated by
CD44H. Cancer Res. 53:3830–3838. 1993.PubMed/NCBI
|
|
16
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Skubitz AP, Taras EP, Boylan KL, Waldron
NN, Oh S, Panoskaltsis-Mortari A and Vallera DA: Targeting CD133 in
an in vivo ovarian cancer model reduces ovarian cancer progression.
Gynecol Oncol. 130:579–587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Akedo H, Shinkai K, Mukai M, Mori Y,
Tateishi R, Tanaka K, Yamamoto R and Morishita T: Interaction of
rat ascites hepatoma cells with cultured mesothelial cell layers: A
model for tumor invasion. Cancer Res. 46:2416–2422. 1986.PubMed/NCBI
|
|
19
|
Stylianou E, Jenner LA, Davies M, Coles GA
and Williams JD: Isolation, culture and characterization of human
peritoneal mesothelial cells. Kidney Int. 37:1563–1570. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Doglioni C, Dei Tos AP, Laurino L,
Iuzzolino P, Chiarelli C, Celio MR and Viale G: Calretinin: A novel
immunocytochemical marker for mesothelioma. Am J Surg Pathol.
20:1037–1046. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma L, Lai D, Liu T, Cheng W and Guo L:
Cancer stem-like cells can be isolated with drug selection in human
ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin.
42:593–602. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kindelberger DW, Lee Y, Miron A, Hirsch
MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW,
Birch C, et al: Intraepithelial carcinoma of the fimbria and pelvic
serous carcinoma: Evidence for a causal relationship. Am J Surg
Pathol. 31:161–169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Domcke S, Sinha R, Levine DA, Sander C and
Schultz N: Evaluating cell lines as tumour models by comparison of
genomic profiles. Nat Commun. 4:21262013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Elias KM, Emori MM, Papp E, MacDuffie E,
Konecny GE, Velculescu VE and Drapkin R: Beyond genomics: Critical
evaluation of cell line utility for ovarian cancer research.
Gynecol Oncol. 139:97–103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Anglesio MS, Wiegand KC, Melnyk N, Chow C,
Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR,
et al: Type-specific cell line models for type-specific ovarian
cancer research. PLoS One. 8:e721622013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McLean K, Gong Y, Choi Y, Deng N, Yang K,
Bai S, Cabrera L, Keller E, McCauley L, Cho KR and Buckanovich RJ:
Human ovarian carcinoma-associated mesenchymal stem cells regulate
cancer stem cells and tumorigenesis via altered BMP production. J
Clin Invest. 121:3206–3219. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grosse-Gehling P, Fargeas CA, Dittfeld C,
Garbe Y, Alison MR, Corbeil D and Kunz-Schughart LA: CD133 as a
biomarker for putative cancer stem cells in solid tumours:
Limitations, problems and challenges. J Pathol. 229:355–378. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ajani JA, Song S, Hochster HS and
Steinberg IB: Cancer stem cells: The promise and the potential.
Semin Oncol. 42 Suppl 1:S3–S17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Motegi H, Kamoshima Y, Terasaka S,
Kobayashi H and Houkin K: Type 1 collagen as a potential niche
component for CD133-positive glioblastoma cells. Neuropathology.
34:378–385. 2014.PubMed/NCBI
|
|
30
|
Okudela K, Woo T, Mitsui H, Tajiri M,
Masuda M and Ohashi K: Expression of the potential cancer stem cell
markers, CD133, CD44, ALDH1, and β-catenin, in primary lung
adenocarcinoma - their prognostic significance. Pathol Int.
62:792–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yano S, Tazawa H, Hashimoto Y, Shirakawa
Y, Kuroda S, Nishizaki M, Kishimoto H, Uno F, Nagasaka T, Urata Y,
et al: A genetically engineered oncolytic adenovirus decoys and
lethally traps quiescent cancer stem-like cells in S/G2/M phases.
Clin Cancer Res. 19:6495–6505. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li
JM, Yang T and Liu W: CD133 expression in osteosarcoma and
derivation of CD133+ cells. Mol Med Rep. 7:577–584.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sangiorgi E and Capecchi MR: Bmi1 is
expressed in vivo in intestinal stem cells. Nat Genet. 40:915–920.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Powell AE, Wang Y, Li Y, Poulin EJ, Means
AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE,
et al: The pan-ErbB negative regulator Lrig1 is an intestinal stem
cell marker that functions as a tumor suppressor. Cell.
149:146–158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Barker N, van Es JH, Kuipers J, Kujala P,
van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H,
Peters PJ and Clevers H: Identification of stem cells in small
intestine and colon by marker gene Lgr5. Nature. 449:1003–1007.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nakanishi Y, Seno H, Fukuoka A, Ueo T,
Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, et
al: Dclk1 distinguishes between tumor and normal stem cells in the
intestine. Nat Genet. 45:98–103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ahmed N, Riley C, Rice G and Quinn M: Role
of integrin receptors for fibronectin, collagen and laminin in the
regulation of ovarian carcinoma functions in response to a matrix
microenvironment. Clin Exp Metastasis. 22:391–402. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shield K, Riley C, Quinn MA, Rice GE,
Ackland ML and Ahmed N: Alpha2beta1 integrin affects metastatic
potential of ovarian carcinoma spheroids by supporting
disaggregation and proteolysis. J Carcinog. 6:112007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sawada K, Mitra AK, Radjabi AR, Bhaskar V,
Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A,
Kenny HA, et al: Loss of E-cadherin promotes ovarian cancer
metastasis via alpha 5-integrin, which is a therapeutic target.
Cancer Res. 68:2329–2339. 2008. View Article : Google Scholar : PubMed/NCBI
|
